Revvity's growth plan depends on a business that has been shrinking.

Revvity wants its laboratory-tools business to move from years of shrinking sales to sustained growth. The long-range plan presented November 13 targets 6% to 8% organic growth for Life Sciences Solutions, a product group representing roughly 45% of company revenue.

In the company's comparison from 2023 through its 2026 estimate, that business's sales declined by an average of about 1% to 3% a year. A recent recovery in the broader Life Sciences segment is encouraging. The plan still needs sustained growth in laboratory tools.

The 2027 view adds a step up

Research by Ticker Byline shows that Revvity's early view of approximately 6% organic growth in 2027 is about one percentage point above the roughly 5% expected for 2026. Our comparison uses the November 3 annual forecast and the new presentation, both excluding the China immunodiagnostics business it has agreed to sell. Fiscal 2026 has 53 weeks; 2027 returns to 52.

The 2027 figures are planning considerations, with formal guidance due on the fourth-quarter results call. Organic growth removes currency movements and the effects of recent acquisitions and disposals, so the intended improvement depends on the continuing business.

Our earlier analysis of Revvity's recovery shows why that matters: the broader Life Sciences segment moved from a 3% organic decline in Q2 to 9% growth in Q3. That segment includes both Life Sciences Solutions and scientific software.

Software helps, but the tools have to recover too

Life Sciences Solutions sells reagents and instruments used to generate biological evidence in laboratories. Management sees demand from faster experimentation and the need to test ideas produced by increasingly powerful software.

Signals Software provides tools for managing scientific work and analyzing data. It represents about 15% of the Life Sciences segment. Revvity's 10% to 12% long-range target for Signals uses annualized portfolio value, a contract measure, rather than reported revenue growth.

The rest of the company also has a role. Revvity targets 5% to 7% long-range organic growth in Diagnostics and 7% to 9% in the combined Life Sciences segment, supporting a company-wide range of 6% to 8%.

Cost cuts have already done some of the work

Revvity says it reduced headcount by approximately 16% and global floor space by about 25% from 2023 to 2026. Its longer-term profit plan combines further efficiency gains with stronger sales.

The company targets approximately 75 basis points of annual adjusted operating-margin expansion, equivalent to three quarters of a percentage point. It sees margins eventually reaching the mid-30% range from an estimated 28.8% in 2026. The adjusted measure excludes costs such as acquired-intangible amortization and restructuring.

For 2027, management outlined about 20 basis points of margin improvement beyond the normal benefit of higher sales spreading fixed costs. It also assumed a flat share count.

The growth plan therefore needs more than a smaller cost base. Investors can test it by watching whether laboratory demand keeps improving and how much of each additional sales dollar becomes profit. The Revvity company profile now follows the 2027 considerations alongside current results, cash and portfolio changes.